Telemonitoring of Elderly with Hypertension and Type 2 Diabetes at the Primary Care Level: Protocol for a Multicentric Randomized Controlled Pilot Study |
| |
Authors: | Matic Mihevc,Č rt Zavrnik,Majda Mori Lukanč ič ,Tina Virtič ,Valentina Prevolnik Rupel,Marija Petek Š ter,Zalika Klemenc Ketiš ,Antonija Poplas Susič |
| |
Affiliation: | 1.Ljubljana Community Health Centre, Primary Healthcare Research and Development Institute, Metelkova 9, 1000, Ljubljana, Slovenia;2.University of Maribor, Faculty of Medicine, Department of Family Medicine, Taborska 8, 2000, Maribor, Slovenia;3.Institute for Economic Research, Kardeljeva ploščad 17, 1000, Ljubljana, Slovenia;4.University of Ljubljana, Faculty of Medicine, Department of Family Medicine, Poljanski nasip 58, 1000, Ljubljana, Slovenia |
| |
Abstract: | IntroductionArterial hypertension (AH) and type 2 diabetes (T2D) represent a significant burden for the public health system, with an exceptionally high prevalence in patients aged ≥65 years. This study aims to test the acceptability, clinical effectiveness, and cost-effectiveness of telemonitoring in elderly patients with AH and T2D at the primary care level.MethodsA m ulti-centre, prospective, randomized, controlled t rial w ill be conducted. Patients a ged ≥ 65 y ears with AH and T2D will be randomized in a 1:1 proportion to a mHealth intervention or standard care group. Patients in the intervention group will measure their blood pressure (BP) twice weekly and blood glucose (BG) once monthly. The readings will be synchronously transmitted via a mobile application to the telemonitoring platform, where they will be reviewed by a general practitioner who will indicate changes in measurement regimen or carry out a teleconsultation. The primary endpoint will be a change in systolic BP (SBP) and glycated haemoglobin (HbA1c) relative to standard care up to 12 months after inclusion. Secondary endpoints will be a change in other observed clinical variables, quality-of-life indexes, and costs.Expected resultsTelemonitoring will be an acceptable method of care associated with significant reductions in SBP and HbA1c levels and an increase in quality-of-life indexes in the intervention group. However, the cost-effectiveness threshold (incremental cost-effectiveness ratio below €25,000/quality-adjusted life year) might not be reached.ConclusionThis study will provide new evidence for scaling up telemonitoring network at the primary care level and modifying telemonitoring protocols to achieve the best clinical and cost-effective outcomes. |
| |
Keywords: | mobile health telemonitoring blood pressure blood glucose HbA1c aged primary health care costs |
|
|